Abstract
Tyrosine kinase inhibitors (TKI) have improved CML response rates, and some are effective against resistance-promoting point mutations in BCR-ABL1. However, in the absence of point mutations, resistance still occurs. Here, we identify a novel pathway mediating resistance which connects p47phox, the organizer subunit of NADPH oxidase-2 (NOX2), with early growth response-1 (Egr-1) and the Src family kinase Fyn. We found up-regulation of p47phox, Egr-1, and Fyn mRNA and protein using paired isogenic CML cell lines and mined data. Isolation of CD34+ cells and tissue microarray staining from blast crisis CML patients confirmed in vivo over-expression of components of this pathway. Knockdown studies revealed that p47phox modulated reactive oxygen species and Egr-1 expression, which, in turn, controlled Fyn expression. Interestingly, Fyn knockdown sensitized TKI-resistant cells to dasatinib, a dual BCR-ABL1/Src inhibitor. Egr-1 knockdown had similar effects, indicating the utility of targeting Fyn expression over activation. Pointedly, p47phox knockdown also restored TKI-sensitivity, indicating that targeting the NOX2 complex can overcome resistance. The NOX2/Egr-1/Fyn pathway was also conserved within TKI-resistant EGFRΔIII-expressing glioblastoma and patient-derived glioblastoma stem cells. Thus, our findings suggest that targeting the NOX2/Egr-1/Fyn pathway may have clinical implications within multiple cancer types; particularly where efficacy of TKI is compromised.
Highlights
The advent of tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the primary oncogene associated with chronic myeloid leukemia (CML), has dramatically increased patient survival rates [1, 2]
To understand how alterations of the redox milieu are associated with TKI-resistance in CML, we first measured the levels of reactive oxygen species (ROS) within two cell line models of acquired mutation-independent resistance
Of the seven NADPH oxidase (NOX) complex family members, NOX1, NADPH oxidase-2 (NOX2), NOX4, NOX5, and DUOX2 have all been identified as isoforms present in CML [27, 33, 35]
Summary
The advent of tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the primary oncogene associated with chronic myeloid leukemia (CML), has dramatically increased patient survival rates [1, 2]. TKI-resistance is a looming clinical problem as the number of patients with detectable disease burden continues to grow [2]. This issue underscores a need for new approaches to treat refractory patients. Single point mutations in BCR-ABL1 are known determinants of TKI-sensitivity [3,4,5,6]. Persistence of CML stem cells (LSC), which are less dependent on BCR-ABL1 rendering them less sensitive to TKI, are another example of point mutation-independent resistance [8]. As stem cell populations are commonly less sensitive to inhibition of oncogenic tyrosine kinases, the identification of novel targetable pathways within those populations is of vital importance
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have